Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Durvalumab and tremelimumab with stereotactic radiotherapy in advanced non-small cell lung cancer
NL-OMON26168Phase 1Not yet recruiting
- Sponsor
- University Medical Center Groningen
- Start
- Oct 2017
- Modality
- PD-1/PD-L1 Inhibitors → Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics, Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 1, open-label trial of durvalumab and tremelimumab in non-small cell lung cancer (NSCLC) (4 cohorts), sponsored by University Medical Center Groningen. Primary endpoint: Maximum tolerated dose and dose-limiting safety. Planned start Oct 2017; status: not yet recruiting.
02
Drugs
durvalumabtremelimumab
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NL-OMON26168.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON26168.